Profile data is unavailable for this security.
About the company
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-15.40m
- Incorporated2020
- Employees9.00
- LocationTiziana Life Sciences Ltd3Rd Floor, 11-12 St. James's SquareLONDON SW1Y 4LBUnited KingdomGBR
- Phone+44 207 495 2379
- Websitehttps://www.tizianalifesciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Athira Pharma Inc | 0.00 | -116.19m | 90.84m | 65.00 | -- | 0.851 | -- | -- | -3.05 | -3.05 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -63.45 | -30.73 | -72.51 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
Aclaris Therapeutics Inc | 31.12m | -77.26m | 91.93m | 91.00 | -- | 0.6472 | -- | 2.95 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
Elutia Inc | 25.05m | -49.46m | 95.21m | 54.00 | -- | -- | -- | 3.80 | -2.35 | -2.34 | 1.24 | -2.07 | 0.5219 | 2.06 | 4.27 | 463,833.30 | -103.05 | -42.93 | -599.50 | -79.34 | 42.01 | 43.32 | -197.48 | -64.16 | 0.5499 | -1.36 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
Assembly Biosciences Inc | 12.95m | -51.36m | 96.04m | 65.00 | -- | 2.64 | -- | 7.42 | -11.22 | -11.22 | 2.76 | 5.95 | 0.1276 | -- | 34.07 | 199,200.00 | -50.60 | -39.69 | -66.58 | -44.03 | -- | -- | -396.63 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
Sangamo Therapeutics Inc | 18.76m | -328.05m | 97.49m | 405.00 | -- | 1.69 | -- | 5.20 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 97.73m | 9.00 | -- | 4.95 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
Immunic Inc | 0.00 | -97.92m | 99.09m | 77.00 | -- | 1.19 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
Beyondspring Inc | 1.75m | -21.03m | 100.15m | 35.00 | -- | -- | -- | 57.19 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
Eledon Pharmaceuticals Inc | 0.00 | -39.85m | 100.50m | 20.00 | -- | 0.8656 | -- | -- | -1.41 | -1.41 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.86 | -38.44 | -51.95 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
Cellectar Biosciences Inc | 0.00 | -50.98m | 102.53m | 20.00 | -- | 10.44 | -- | -- | -3.17 | -3.17 | 0.00 | 0.789 | 0.00 | -- | -- | 0.00 | -176.58 | -83.69 | -295.36 | -99.80 | -- | -- | -- | -- | -- | -4.81 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
CytomX Therapeutics Inc | 119.18m | 16.53m | 103.63m | 120.00 | 6.73 | -- | 5.58 | 0.8696 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
Hongchang International Co Ltd | 2.67m | -365.80k | 103.82m | 8.00 | -- | 2.62 | -- | 38.93 | -0.0006 | -0.0006 | 0.0055 | 0.0763 | 0.0993 | -- | 175.86 | -- | -1.36 | -7.98 | -1.42 | -10.94 | 3.03 | 11.47 | -13.72 | -64.88 | 5.86 | -- | 0.2263 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Geode Capital Management LLCas of 31 Mar 2024 | 215.83k | 0.21% |
HSBC Bank Plc (Broker)as of 31 Mar 2024 | 164.23k | 0.16% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 85.87k | 0.08% |
Ausdal Financial Partners, Inc.as of 31 Mar 2024 | 55.70k | 0.05% |
EWA LLCas of 31 Mar 2024 | 55.30k | 0.05% |
Zhang Financial LLCas of 31 Mar 2024 | 52.06k | 0.05% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 39.66k | 0.04% |
UBS Securities LLCas of 31 Mar 2024 | 31.85k | 0.03% |
Bank of America, NA (Private Banking)as of 31 Mar 2024 | 21.29k | 0.02% |
Barclays Bank Plc (Private Banking)as of 31 Mar 2024 | 17.50k | 0.02% |